However, some transporters, including OATP1B1/3 and OAT3, demonstrated inhibition following treatment with GLP-1 RAs and a dual GLP-1/GIP RA in vitro, suggesting that the assessment of transporter-mediated DDI by GLP-1 RAs may be necessary (Table 3)
Severe or worsening pain that intensifies over 24-48 hours rather than improving suggests possible complications beyond normal injection site reactions
Individual gastric function baseline determines risk
Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report
Headaches : Mild headaches are possible, especially in the first few weeks
European Journal of Pharmaceutical Sciences, 2013